Research on the Relationship between the School-Running Characteristics of Private Colleges and Universities and the Development Objectives of the Government

The development objectives of the Chinese government have a guiding effect on the school-running characteristics of private colleges and universities.This paper explores the relationship between the characteristics of private colleges and universities and the development objectives of the provincial government,using Jiangsu Province as a case study.All the schools have the consciousness of fully considering the development objectives of Jiangsu Province when formulating the school-running characteristics.Their characteristics all contain some training methods,training courses,or institutional construction aiming at the development objectives.Most universities can support the government’s objectives on employment and innovation.Only a third of the schools provide government support for science research.Private colleges and universities should make full use of the free and flexible advantages of private education,combine them with the continuous changes of policies and markets,and create clear,scientific,and dynamic school-running characteristics,in order to achieve long-term development.

Informationized Technological Path for the School-running Risk Prevention and Supervision of Private Colleges and Universities under the Background of the Internet

At present,with the decrease of the educational population and the gradual deepening of the higher educational reform,the development of the private colleges and universities is facing various contradictions and challenges.The development concept of"innovation,coordination,green,open and sharing"put forward at the Fifth Plenary Session of the Eighteenth Central Committee of the CPC provides the value guidance and the practical basis for the private colleges and universities to renew their development concepts and solve their development problems.

Why a P value<0.05 does not necessarily mean statistical significance:controversy over overall survival results of the ORIENT-11 trial

On February 10,2022,the U.S.Food and Drug Administration(FDA)’s Oncologic Drugs Advisory Committee voted 14-1 against using data from the ORIENT-11 trial to support a biologics license application for sintilimab injection plus pemetrexed and platinum-based chemotherapy as first-line treatment for patients with nonsquamous non-small cell lung cancer(NSCLC)1.One major reason was that the FDA claimed overall survival(OS)was not statistically tested in ORIENT-11,while previous regular approvals were granted on the basis of statistically significant improvements in OS2.This may be a surprise to some physicians,as the ORIENT-11 trial previously reported improved OS with a hazard ratio(HR)of 0.60(95%confidence interval[CI]:0.45–0.79)and a P value of 0.00033,which is far below the commonly accepted threshold of 0.05 for declaring statistical significance.Some may argue that the OS results of ORIENT-11 were not considered statistically significant by the FDA because OS was only a secondary endpoint.However,in the KEYNOTE-024 trial4,which compared pembrolizumab with chemotherapy in patients with previously untreated advanced NSCLC with PD-L1 expression on at least 50%of tumor cells,OS was also a secondary endpoint.Nevertheless,the OS benefit of the KEYNOTE-024 trial was acknowledged by the FDA and included in the drug label5.The fundamental reason why OS results of ORIENT-11 were not considered statistically significant by the FDA is that the OS endpoint was not included in the multiplicity control strategy.